Femeda is a single use device for the treatment of incontinence in females. It is a self-contained muscle stimulator specifically for pelvic floor muscles.
The Company initiated a soft launch under the Pelviva brand in August 2014. The Company is planning to recruit 6,700 trial users and have circa 1,500 loyal customers by the middle of 2015. The targeted exit is at £30m+ within 18 months with targeted buyers including Procter & Gamble UK; SCA; Reckitt Benckiser and Ontex Global.